Concepts (103)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Genetic Predisposition to Disease | 6 | 2024 | 628 | 1.030 |
Why?
|
| Receptors, Calcitriol | 2 | 2024 | 69 | 1.030 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2024 | 767 | 1.000 |
Why?
|
| Prostatic Neoplasms | 6 | 2020 | 935 | 0.720 |
Why?
|
| Promoter Regions, Genetic | 2 | 2020 | 515 | 0.700 |
Why?
|
| Interleukin-10 | 1 | 2020 | 75 | 0.690 |
Why?
|
| MicroRNAs | 1 | 2024 | 426 | 0.650 |
Why?
|
| Alleles | 4 | 2020 | 321 | 0.520 |
Why?
|
| Breast Neoplasms | 2 | 2024 | 1502 | 0.510 |
Why?
|
| Genotype | 6 | 2024 | 730 | 0.500 |
Why?
|
| Case-Control Studies | 7 | 2024 | 1130 | 0.480 |
Why?
|
| Smoking | 1 | 2020 | 940 | 0.440 |
Why?
|
| Neoplasms | 1 | 2022 | 1103 | 0.410 |
Why?
|
| HLA-DQ Antigens | 1 | 2008 | 6 | 0.330 |
Why?
|
| Trachoma | 1 | 2008 | 2 | 0.330 |
Why?
|
| HLA-B Antigens | 1 | 2008 | 11 | 0.330 |
Why?
|
| HLA-DR Antigens | 1 | 2008 | 21 | 0.330 |
Why?
|
| Endemic Diseases | 1 | 2008 | 20 | 0.320 |
Why?
|
| Middle Aged | 10 | 2024 | 10129 | 0.260 |
Why?
|
| Aged | 6 | 2024 | 6741 | 0.240 |
Why?
|
| Trypanocidal Agents | 2 | 2016 | 39 | 0.230 |
Why?
|
| Haplotypes | 3 | 2020 | 182 | 0.230 |
Why?
|
| Trypanosoma cruzi | 2 | 2016 | 149 | 0.210 |
Why?
|
| Humans | 15 | 2024 | 37093 | 0.210 |
Why?
|
| Insect Control | 1 | 2021 | 4 | 0.200 |
Why?
|
| Pest Control, Biological | 1 | 2021 | 7 | 0.200 |
Why?
|
| Hydrocortisone | 1 | 2022 | 78 | 0.200 |
Why?
|
| Triticum | 1 | 2021 | 20 | 0.200 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 97 | 0.170 |
Why?
|
| Anemia, Sickle Cell | 1 | 2021 | 183 | 0.170 |
Why?
|
| DNA Methylation | 1 | 2022 | 325 | 0.170 |
Why?
|
| Adult | 6 | 2024 | 11712 | 0.160 |
Why?
|
| Receptor, Notch1 | 1 | 2018 | 17 | 0.160 |
Why?
|
| Bacteria | 1 | 2021 | 255 | 0.160 |
Why?
|
| GTPase-Activating Proteins | 1 | 2018 | 29 | 0.160 |
Why?
|
| Chromosome Mapping | 1 | 2018 | 188 | 0.150 |
Why?
|
| Cell Line, Tumor | 1 | 2024 | 2231 | 0.150 |
Why?
|
| Prostate-Specific Antigen | 2 | 2015 | 118 | 0.150 |
Why?
|
| Vitis | 1 | 2017 | 31 | 0.150 |
Why?
|
| BRCA2 Protein | 1 | 2017 | 37 | 0.150 |
Why?
|
| BRCA1 Protein | 1 | 2017 | 48 | 0.140 |
Why?
|
| DNA, Neoplasm | 1 | 2017 | 92 | 0.140 |
Why?
|
| Risk Assessment | 1 | 2020 | 753 | 0.140 |
Why?
|
| Female | 7 | 2024 | 20969 | 0.140 |
Why?
|
| Tubulin | 1 | 2016 | 88 | 0.130 |
Why?
|
| Chagas Disease | 1 | 2016 | 98 | 0.130 |
Why?
|
| Prostatic Hyperplasia | 1 | 2015 | 34 | 0.130 |
Why?
|
| Male | 9 | 2022 | 20025 | 0.130 |
Why?
|
| Plant Extracts | 1 | 2017 | 286 | 0.120 |
Why?
|
| Risk Factors | 2 | 2020 | 3562 | 0.110 |
Why?
|
| Carrier Proteins | 1 | 2015 | 305 | 0.110 |
Why?
|
| Genes, MHC Class I | 1 | 2013 | 13 | 0.110 |
Why?
|
| Genes, MHC Class II | 1 | 2013 | 20 | 0.110 |
Why?
|
| Multiple Sclerosis | 1 | 2013 | 45 | 0.110 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2018 | 807 | 0.110 |
Why?
|
| Mutation | 1 | 2017 | 1095 | 0.100 |
Why?
|
| Cytotoxins | 1 | 2012 | 11 | 0.100 |
Why?
|
| Genetic Markers | 1 | 2012 | 142 | 0.100 |
Why?
|
| Naphthoquinones | 1 | 2012 | 36 | 0.100 |
Why?
|
| Histocompatibility Testing | 1 | 2008 | 7 | 0.080 |
Why?
|
| Tanzania | 1 | 2008 | 7 | 0.080 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2008 | 69 | 0.080 |
Why?
|
| Mouth Mucosa | 1 | 2008 | 34 | 0.080 |
Why?
|
| Porins | 1 | 2008 | 19 | 0.080 |
Why?
|
| Gene Frequency | 1 | 2008 | 195 | 0.080 |
Why?
|
| Chlamydia trachomatis | 1 | 2008 | 68 | 0.080 |
Why?
|
| DNA, Bacterial | 1 | 2008 | 186 | 0.080 |
Why?
|
| Flow Cytometry | 1 | 2008 | 399 | 0.070 |
Why?
|
| Rural Population | 1 | 2008 | 294 | 0.070 |
Why?
|
| Young Adult | 3 | 2022 | 4268 | 0.070 |
Why?
|
| Adolescent | 2 | 2022 | 5363 | 0.060 |
Why?
|
| Risk | 2 | 2015 | 267 | 0.060 |
Why?
|
| Immunoglobulin A | 1 | 2022 | 58 | 0.050 |
Why?
|
| Saliva | 1 | 2022 | 107 | 0.050 |
Why?
|
| Immunoglobulin G | 1 | 2022 | 237 | 0.050 |
Why?
|
| Sex Characteristics | 1 | 2022 | 230 | 0.050 |
Why?
|
| Immunohistochemistry | 1 | 2022 | 893 | 0.050 |
Why?
|
| DNA | 1 | 2022 | 574 | 0.040 |
Why?
|
| Phenotype | 1 | 2021 | 689 | 0.040 |
Why?
|
| Recurrence | 1 | 2017 | 131 | 0.040 |
Why?
|
| Lipid Peroxidation | 1 | 2017 | 140 | 0.040 |
Why?
|
| DNA Mutational Analysis | 1 | 2017 | 93 | 0.040 |
Why?
|
| Age of Onset | 1 | 2017 | 100 | 0.040 |
Why?
|
| Superoxide Dismutase | 1 | 2017 | 155 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2017 | 275 | 0.040 |
Why?
|
| Mice | 2 | 2021 | 5913 | 0.030 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2016 | 269 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 2018 | 251 | 0.030 |
Why?
|
| Trypsin Inhibitor, Kazal Pancreatic | 1 | 2015 | 5 | 0.030 |
Why?
|
| Prognosis | 1 | 2018 | 739 | 0.030 |
Why?
|
| Drug Design | 1 | 2016 | 162 | 0.030 |
Why?
|
| United States | 2 | 2017 | 4223 | 0.030 |
Why?
|
| Child | 1 | 2022 | 3131 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2016 | 1180 | 0.030 |
Why?
|
| Africa, Western | 1 | 2012 | 18 | 0.030 |
Why?
|
| Prevalence | 1 | 2017 | 1455 | 0.030 |
Why?
|
| Linkage Disequilibrium | 1 | 2012 | 85 | 0.030 |
Why?
|
| NIH 3T3 Cells | 1 | 2012 | 61 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2017 | 2379 | 0.020 |
Why?
|
| Animals | 2 | 2021 | 15081 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2012 | 333 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2012 | 661 | 0.020 |
Why?
|
| Puerto Rico | 1 | 2013 | 1378 | 0.020 |
Why?
|